NEUROMETRIX INC (NURO) Stock Price, Forecast & Analysis
USA - NASDAQ:NURO - US6412558800 - Common Stock
NURO Key Statistics, Chart & Performance
The current stock price of NURO is 4.58 USD. In the past month the price increased by 3.6%. In the past year, price increased by 6.51%.
NURO Latest News, Press Relases and Analysis
NURO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About NURO
Company Profile
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2004-07-22. The firm's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The firm has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. The company operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
Company Info
NEUROMETRIX INC
1000 Winter Street
Waltham MASSACHUSETTS 01801 US
CEO: Shai N. Gozani
Employees: 13
Phone: 17818909989
NEUROMETRIX INC / NURO FAQ
Can you describe the business of NEUROMETRIX INC?
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2004-07-22. The firm's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The firm has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. The company operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
What is the current price of NURO stock?
The current stock price of NURO is 4.58 USD. The price increased by 5.05% in the last trading session.
Does NURO stock pay dividends?
NURO does not pay a dividend.
What is the ChartMill rating of NEUROMETRIX INC stock?
NURO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is NURO stock listed?
NURO stock is listed on the Nasdaq exchange.
NURO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NURO. When comparing the yearly performance of all stocks, NURO is one of the better performing stocks in the market, outperforming 79.56% of all stocks.
NURO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NURO. NURO has a great financial health rating, but its profitability evaluates not so good.
NURO Financial Highlights
Over the last trailing twelve months NURO reported a non-GAAP Earnings per Share(EPS) of -4.03. The EPS decreased by -98.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.94% | ||
| ROE | -54.54% | ||
| Debt/Equity | 0 |